GlobeNewswire

Corporate R&D spending hits record highs for the Top 1000, despite concerns of economic protectionism

Share
  • Annual worldwide R&D spending breaks through $700bn for the top 1000 corporate R&D spenders for first time
  • 25% of executives surveyed reported having already experienced some pressure to change how or where they conduct innovation
  • Amazon is the world's largest corporate spender on R&D at over $16bn
  • Alphabet surpasses Apple, according to a global survey of R&D executives, as the Most Innovative Company and for the first time a Chinese company, Alibaba joins the Top 10 Most Innovative Companies list

NEW YORK, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Annual worldwide corporate R&D spending broke through $700bn in annual investment, according to an annual analysis of R&D spending across 1000 global public companies by PwC's Strategy&.

It shows corporate R&D spending increased a steady 3% in the past year, bouncing back from less than 1% increase previously.

However, in a global survey with 562 executive participants, R&D leaders expressed concerns about the growing heat of rhetoric about economic nationalism - and its potential impact on where companies invest in R&D how they conduct innovation.

Overall, 52% of respondents say that a general move toward economic nationalism will have a moderate or significant impact on their companies' R&D efforts.

Major companies have been conducting some R&D outside their headquarters countries for decades. In 2015 it was determined that 94% of major corporations conduct their R&D in multiple countries.  But increasing attention on regulations and policies for visas, labor movement, and the regulations governing the sharing of knowledge and technology are causing some companies to question how sustainable their integrated global innovation networks are.

Nearly 33% of R&D executives surveyed, report that they have already felt the effects of economic nationalism on their R&D talent acquisition or retention because of visa or work restrictions - either losing employees, seeing less talent available, or in hiring more local talent.

  • Although nearly 66% of all participants surveyed say they have not experienced pressure to change their approach to innovation in their headquarters country to date, 23% say they have already experienced such pressure in another country.
  • Almost 50% of the companies in North America plan to make changes to their R&D programs over the next two years in response to the changing political environment.
  • Survey participants believed US, UK, and China could be most at risk from potential changes in policy that could impact R&D investment. Both the US and UK's talent flow could be at risk of potential disruption while China's decline in corporate R&D spending and reliance on R&D investment from abroad could be at risk.   
  • Canada, Germany, and France are likely to gain if protectionist policies broadly become a reality.

"It's been a year of highs and lows for R&D. Record levels of investment, next to unprecedented drops in alignment between innovation and business strategies. There's no doubt that uncertainty is causing concern for medium and long term plans, irrespective of whether policy realities actually  follow political rhetoric," comments Barry Jaruzelski, Principal, PwC US, Strategy& 

"Although the goals and levels of investment in corporate innovation will likely not change if economic nationalism continues to develop, the global innovation model would need to evolve. At many companies, what is now a nimble, interdependent network may become a group of more autonomous hubs, hiring specialist technical talent in local regional markets and opening future R&D centers in regional markets. It could mean companies losing efficiency and taking on higher costs if it is not managed effectively," Commented Jaruzelski.

Global Innovation 1000
The Strategy& Global Innovation 1000 study analyses spending at the world's 1000 largest publicly listed corporate R&D spenders and is now in its 13th year

  • Amazon is the largest spender on R&D in the Global Innovation 1000 study, the first time the top spender is a high tech firm. All top four spenders are high tech companies.
  • Overall, Software & Internet industry companies continue to increase their year-on-year R&D spending, and the analysis shows that by 2018, Healthcare companies will surpass Computing & Electronics to become the largest industry in terms of R&D spending - the first time in 12 years of analysis.
  • Overall, Computing & Electronics, Healthcare, and Automotive are the top three industry sectors and represented 61.3% of global R&D spending in 2017.
  • Alphabet, Amazon, GE, IBM and Microsoft all increased their ranking in the 10 Most Innovative Companies list, according to a global survey of R&D executives
  • R&D spending by companies based in China declined for the first time in the study, it increased in Japan for first time in 4 years, and continued to grow moderately in North America.

Notes to Editors

  1. In 2016, worldwide R&D spending among the world's 1000 largest corporate R&D spenders increased 0.04% in 2016 to $680 billion.
  2. R&D intensity - the measure of R&D spending relative to sales - hit an all-time study high of 4.5%: a rise of 6% year on year amongst the world's top 1000 R&D spenders.
  3. Companies that deployed 60% or more of their R&D spending outside their headquarters country earned a premium of 30% on operating margin and return on assets, and 20% on growth in operating income over their more domestically focused competitors.
  4. Uncertainty in economic policy may also be contributing to an unprecedented 19% drop in high alignment between innovation and business strategies within companies, making companies cautious about how to plan for their innovation strategy in the short and medium term.
  5. The study finds that companies ranked in the list of top ten most innovative companies outperform the top ten R&D spenders on financial metrics including growth, EBITDA, and market capitalisation.
  6. China's corporate R&D spending had experienced double-digit growth rates for many years, but in 2017 the country saw a 3.3% decline in corporate R&D spending for the first time in the study. 80% of China's R&D spend in 2015 was performed by companies headquartered in other countries. The combination of these trends for China makes the country vulnerable to potential disruptions of R&D investment coming from abroad.

About Strategy&
Strategy& is a global team of practical strategists committed to helping you seize essential advantage. We do that by working alongside you to solve your toughest problems and helping you capture your greatest opportunities. We bring 100 years of strategy consulting experience and the unrivaled industry and functional capabilities of the PwC network to the task. We are part of the PwC network of firms in 157 countries with more than 223,000 people committed to delivering quality in assurance, tax, and advisory services.

© 2017 PwC. All rights reserved. PwC refers to the PwC network and/or one or more of its member firms, each of which is a separate legal entity. Please see www.pwc.com/structure for further details.

Follow us on Twitter , LinkedIn, and YouTube

Contact:

Rowena Mearley, PwC Global Media Relations
Tel: + 1 646 313 0937
E-mail: rowena.j.mearley@pwc.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PwC via Globenewswire

About GlobeNewswire

GlobeNewswire
GlobeNewswire



Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Hexatronic Group AB (publ) Delårsrapport januari – mars 202426.4.2024 07:00:00 CEST | Pressmeddelande

Hexatronic Group AB (publ) Delårsrapport januari – mars 2024 Fortsatt starkt operativt kassaflöde och bidrag från nya fokusområden Första kvartalet (1 januari – 31 mars 2024) Nettoomsättningen minskade med 16 procent till 1 782 MSEK (2 115). Omsättningen minskade organiskt med 27 procent.EBITA minskade med 54 procent till 168 MSEK (365), motsvarande en EBITA-marginal om 9,4 procent (17,2).Rörelseresultatet (EBIT) minskade med 59 procent till 138 MSEK (340), motsvarande en rörelsemarginal om 7,7 procent (16,1).Nettoresultatet minskade med 73 procent till 61 MSEK (224).Resultat per aktie efter utspädning uppgick till 0,31 SEK (1,09).Skuldsättning (nettoskuld/ EBITDA (proforma), R12) uppgick till 2,0 ggr, jämfört med 1,7 per 31 december 2023.Kassaflöde från löpande verksamheten uppgick till 270 MSEK (28). Väsentliga händelser under kvartalet Styrelsen föreslår till årsstämman att ingen utdelning ska utgå för räkenskapsåret 2023.Hexatronic slår samman de två helägda svenska dotterbolagen H

Hexatronic meddelar förändringar i koncernledningen25.4.2024 18:00:00 CEST | Pressmeddelande

Pressmeddelande 25 april, 2024 Göteborg Sverige Hexatronic meddelar förändringar i koncernledningen Hexatronic Group AB (publ) meddelar två förändringar i bolagets koncernledning. Jakob Skov, Head of focus area Harsh Environment, blir från och med april 2024 en del av bolagets koncernledning och i juni 2024 tillträder Pernilla Grennfelt i en ny roll som Head of Investor Relations och kommer då också att ingå i bolagets koncernledning. Jakob Skov rekryterades till Hexatronic 2022 och har sedan dess framgångsrikt lett Hexatronics fokusområde Harsh Environment som under det senaste året vuxit till en signifikant del av koncernens totala försäljning. Jakob Skov har lång erfarenhet från ledande roller på flera globala bolag inom avancerad fiberoptik. Han har en MSc in International Business Administration and Finance från Aarhus School of Economics. ”Harsh Environment har under 2023 vuxit till en signifikant del av gruppens totala försäljning och det är också ett viktigt tillväxtområde för

Corline Biomedical publicerar årsredovisning för 202323.4.2024 17:48:21 CEST | Pressmeddelande

Corline Biomedical AB (”Corline”) publicerar idag sin årsredovisning för bokföringsåret 2023, vilken tillgängliggörs via bolagets hemsida www.corline.se. För mer information om Corline, vänligen kontakta Henrik Nittmar, VD Telefon: +46 (0)18 71 30 90 E-post: henrik.nittmar@corline.se Redeye AB är Corlines Certified Adviser. Corline Biomedical AB, noterat på First North Growth Market (CLBIO), arbetar med den kroppsegna substansen heparin och har utvecklat en portfölj med läkemedelskandidater för användning i anslutning till organ- och celltransplantation. Bolaget är i färd med att inleda fas 2-studier för Renaparin®, en kandidat för vilken Corline har erhållit särläkemedelsdesignering (”Orphan Drug”) i Europa och USA och som är under utveckling för att förbättra utfallet av njurtransplantation. Sedan tidigare ytbelägger bolaget medicintekniska produkter och har bland annat behandlat över 100 000 hjärtstentar som implanterats i patienter. Bolaget har tecknat avtal om samarbete med ett an

Beslut vid årsstämman i HMS Networks23.4.2024 11:50:00 CEST | Pressmeddelande

HMS Networks AB (publ) har den 23 april 2024 hållit årsstämma. I samtliga ärenden beslutade stämman i enlighet med styrelsens och valberedningens förslag. I det följande redogörs för de viktigaste beslutens huvudsakliga innehåll. VINSTDISPOSITION Årsstämman beslutade att bifalla styrelsens förslag om utdelning med 4,40 kr per aktie. Som avstämningsdag för utdelning fastslogs den 25 april 2024. Utdelning beräknas därmed att utsändas genom Euroclear Swedens försorg den 30 april 2024. FASTSTÄLLANDE AV RESULTAT- OCH BALANSRÄKNING OCH ANSVARSFRIHET Årsstämman beslutade att fastställa av styrelsen framlagd resultat- och balansräkning för HMS Networks AB och koncernen. Styrelsen och bolagets verkställande direktör beviljades ansvarsfrihet för räkenskapsåret 2023. VAL AV STYRELSE OCH REVISOR SAMT BESLUT OM ARVODEN Årsstämman beslutade i enlighet med valberedningens förslag, nämligen att sex (6) ordinarie styrelseledamöter väljs utan några styrelsesuppleanter,att ett (1) registrerat revisionsbo

Elanders AB: Rapport från årsstämman 202419.4.2024 14:18:43 CEST | Pressmeddelande

Stämman, som leddes av styrelsens ordförande Dan Frohm, beslöt att: fastställa resultat- och balansräkningen samt koncernresultat- och koncernbalansräkningen,bevilja styrelsens ledamöter och verkställande direktören ansvarsfrihet för verksamhetsåret 2023,enligt styrelsens förslag i kallelsen fastställa att utdelning för 2023 lämnas med 4,15 kronor per aktie samt att avstämningsdagen för utdelning är den 23 april 2024, vilket innebär att utdelningen beräknas utsändas genom Euroclear Sweden AB den 26 april 2024,enligt förslaget i kallelsen för verksamhetsåret 2024 bevilja styrelsen arvode inklusive utskottsarbete om totalt 4 512 600 kronor att fördelas inom styrelsen såsom angivits i kallelsen,enligt förslaget i kallelsen till styrelseledamöter för tiden intill dess att årsstämman 2025 hållits utse: Carl Bennet (omval) Ulrika Dellby (omval) Eva Elmstedt (omval) Dan Frohm (omval) Erik Gabrielson (omval) Anna Hallberg (omval) Anne Lenerius (omval) Magnus Nilsson (omval) Johan Trouvé (omval

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye